A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Status:
Recruiting
Trial end date:
2025-08-12
Target enrollment:
Participant gender:
Summary
This 2-year study will evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18
years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve
to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent
Phase III study in children and adolescents.